Trichotillomania Clinical Trial
Official title:
Cognitive Training in Patients With Trichotillomania (Hair-pulling Disorder)
The principal aim of this study is to establish the impact of Cognitive Training in patients
with primary Hair-pulling Disorder. Half of the participants will be training with the true
training intervention and the other half with the active control intervention.
Study findings will also provide information on whether an internet based CT intervention,
done at patients' homes, is feasible as a mode of treatment for HPD patients in SA.
Introduction and conceptualization Hair-pulling disorder (HPD) has not received much
attention in comparison to other psychiatric illnesses. Considering South African research,
only a limited number of studies have focused on HPD with minimal focus on treatment
interventions. Several treatments with regards to pharmacotherapy and psychotherapy have been
developed and investigated. Evidence suggests limited efficacy of these treatments, thus
there is a need for an intervention that shows better efficacy in symptom reduction with
longer maintenance of treatment gains, whilst also being cost-effective and easily
accessible. Studies have indicated that patients with HPD experience difficulty in working
memory (WM), impulse control (IC) and emotion regulation (ER). The involvement of the
frontoparietal circuitry, as well as frontal cortex, amygdalo-hippocampal formation and
putamen have been specified in HPD. WM and ER circuitry are both based in the frontoparietal
neural circuit, and thus training of WM shows potential to also address ER difficulties. An
intervention focusing on WM training, may promise to address difficulties in IC and ER, and
thus be appropriate in the treatment of patients with HPD. Cognitive training (CT) is a novel
intervention that focuses on enhancing executive functioning and more specifically WM. WM
tasks in CT also focus on the frontoparietal network which plays a role in ER, and therefore
when this network is activated by executive functioning tasks, ER should improve. The
positive impact of computerized cognitive training (CCT) on neuroplasticity in these
indicated pathways have recently been acknowledged. Psychotherapeutic support might not be
readily available or accessible to most people in developing countries, such as South Africa.
Indeed, locally the physical distance from mental health centres and cost of individual
sessions with health care professionals, are challenging - preventing patients finding the
help that they need. CT can thus be a more accessible and cost-effective alternative. Cogmed
Working Memory Training, an internet-based CT program, will be investigated for its efficacy
in the treatment of HPD.
Purpose of the study: The principal aim of this project is to establish the impact of CT in
patients with primary HPD. Study findings will also provide information on whether an
internet based CT intervention, done at patients' homes, is feasible as a mode of treatment
for HPD patients in SA. The proposed research will focus on the following objectives: To
determine the effect of CT (25 sessions over 5 weeks) on WM, ER, IC and hair-pulling severity
(HPS), in patients with HPD. To determine whether the effect of the true CT program on WM,
ER, IC and HPS differed from that of the active control program. To determine whether effects
are maintained at 3 months post-intervention. To qualitatively explore participants'
subjective experience of the intervention process and responses to CT (in terms of WM, ER, IC
and HPS).
It is hypothesised that after 5 weeks of CT, the treatment HPD group will show significant
improvement in WM, ER, IC and significant reduction in HPS. The effect of the true CT program
on WM, ER, IC and HPS will be significantly different from the active control group. During a
3-month follow-up evaluation, the HPD intervention group will have maintained reduction in
symptoms after the treatment, compared to the active control HPD group. The treatment HPD
group will generally be positive about the effects of CT on HPD and their functioning at
post-intervention and 3-month follow-up and consider CT as easy to use and affordable.
Study design: The study design is a 5-week, 25-session intervention study with an active
control, and 3-month follow-up evaluation. As a registered clinical psychologist, the
principal investigator has the expertise to diagnose, do clinical interviews, and implement
the psychometric battery pre and post intervention. Inclusion criteria is a primary diagnosis
of HPD (DSM-5); Adults (18 years and older); Fluent in English; Access to the internet for
the duration of their study participation. Exclusion criteria is any significant current DSM
comorbidity; Montgomery-Asberg Depression Rating Scale (MADRS) Score > 20 to exclude patients
with comorbid depressive syndromes; Previous exposure to cognitive training (previous 'brain
training' games on cell phone and/or computer allowed). The criteria will be assessed during
the screening procedure. Participants will enter the study as recruited and randomly assigned
to the treatment or active control group. Participants entering the study will be randomized
into the intervention or active control group, using a randomization list provided by the
statistician. The intervention task (Cogmed QM) and the placebo (Jigsaw Puzzles) differ
significantly. The principal investigator will not be blind to the group that the
participants are in, whereas the participants will be blind to their group inclusion. It is
aimed to achieve a sample size of at least 40 (20 treatment, 20 active control). This is
comparable to group sizes in other HPD treatment studies. The research method is based in
embedded theory design, utilizing both quantitative and qualitative components. The benefit
of this hybrid approach is to be able to investigate and describe subject matter with
statistical power, as well as being able to comment on the participant's experience, thus
creating a richer and more holistic description of the research theme. The quantitative
research consists of the pre- and post intervention assessment battery, 3-month follow-up
evaluation and continuous information provided by the treatment intervention (Cogmed). The
qualitative data analysis will be done on semi-structured interviews, as part of the pre- and
post assessment battery and 3-month follow-up evaluation. Pre- and post intervention data
collection will be done by the principal investigator by means of the assessment battery
including both quantitative and qualitative measures. Statistical analysis will be conducted
using mixed model repeated measures ANOVA, which is most suitable for dealing with possible
lost to follow-up. Patients in the study will be treated as random effects (randomly selected
from a larger population). Treatment (intervention vs placebo) and time (pre, post, 3 months)
will be treated as fixed effects. The treatment*time interaction effect will be the primary
effect of investigation because it tests whether the change over time is the same for the two
groups. If the intervention has a different effect to the placebo, then this interaction
effect should be significant. Post hoc testing will be done using Fisher Least Significant
Difference (LSD) testing. Normality assumptions will be checked for all analyses and
appropriately dealt with if necessary, based on the nature of the data. A 5% significance
level will be used as guideline for significant results. The qualitative data will be
analysed using an interpretative phenomenological approach (TerreBlanche, Durrheim, & Kelly,
2010), utilizing a qualitative data analysis software program, Atlas.ti.
Anticipated benefits and risks: CT has not been investigated as a treatment intervention for
HPD and reduction of HPS cannot be guaranteed. However, HPS may reduce during the true CT
program. Participants, who are part of the placebo group, will get the opportunity to access
the true CT program on completion of the study. Except for the fact that they might not be in
the treatment group for the duration of the study due to randomization, there are no known
risks involved in participation.
Ethical Considerations: The study procedures, risks and benefits will be communicated in lay
terminology to all participants (verbally and in writing) in Afrikaans or English. All data
collected will be kept strictly confidential and study results made public and published
without compromising confidentiality. The demographics questionnaire will be removed from the
questionnaire pack to ensure that the completed questionnaires and the demographic details
cannot be linked. Personal identifying details such as the name and contact information will
not be recorded on the electronic database. All participants will be allocated a unique study
code on the electronic database. Identifiers linked to a study code will be kept in a
separate, password protected file. Only the principal investigator will have access to this
information. It will be clearly indicated that the participant is free to withdraw
participation from this trial, without consequence. Participating individuals will incur no
costs.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01445444 -
Habit Reversal Training for Children and Adolescents With Trichotillomania
|
N/A | |
Completed |
NCT04559750 -
Internet CBT for Trichotillomania and Skin Picking Disorder
|
N/A | |
Completed |
NCT01638975 -
Response Inhibition Training for Individuals With Trichotillomania
|
N/A | |
Completed |
NCT00993265 -
N-Acetylcysteine for Pediatric Trichotillomania
|
Phase 2 | |
Completed |
NCT00917098 -
Examining Behavior Therapy for Trichotillomania in Children and Adolescents
|
N/A | |
Recruiting |
NCT00552266 -
Methylphenidate in ADHD With Trichotillomania
|
Phase 4 | |
Completed |
NCT03530800 -
Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors
|
Phase 2/Phase 3 | |
Completed |
NCT01984333 -
Online Response Inhibition Training for Trichotillomania
|
N/A | |
Completed |
NCT00740909 -
Cognitive Behavioral Therapy for Trichotillomania
|
Phase 1/Phase 2 | |
Recruiting |
NCT05003401 -
Leveraging Technological Advancements to Improve the Treatment of Trichotillomania
|
N/A | |
Completed |
NCT01875445 -
Inositol in Trichotillomania
|
Phase 2 | |
Completed |
NCT03486041 -
Comprehensive Behavioral (ComB) Model of Treatment for Trichotillomania
|
N/A | |
Completed |
NCT02473913 -
Milk Thistle in Trichotillomania in Children and Adults
|
Phase 2 | |
Completed |
NCT00872742 -
Testing a New Therapy for Trichotillomania
|
Phase 2 | |
Completed |
NCT00182507 -
Olanzapine in the Treatment of Hair Pulling (Trichotillomania)
|
Phase 4 | |
Completed |
NCT00947154 -
Trial of Aripiprazole in Trichotillomania
|
N/A | |
Completed |
NCT00354770 -
N-Acetyl Cysteine in Trichotillomania
|
Phase 2 | |
Completed |
NCT00004550 -
Evaluation and Follow-up of Individuals With Obsessive-Compulsive Disorder and Related Conditions
|
N/A | |
Completed |
NCT01878110 -
Efficacy of COMB (Comprehensive Behavioral) Model of Treatment of Trichotillomania
|
N/A | |
Active, not recruiting |
NCT01075672 -
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
|
N/A |